Glaukos Co. (NYSE:GKOS) Shares Sold by Sei Investments Co.

Sei Investments Co. decreased its stake in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 16.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 88,690 shares of the medical instruments supplier's stock after selling 17,633 shares during the quarter. Sei Investments Co. owned approximately 0.16% of Glaukos worth $13,298,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. IFP Advisors Inc bought a new position in shares of Glaukos during the 4th quarter worth $43,000. Asset Planning Inc purchased a new stake in Glaukos in the fourth quarter worth about $90,000. Picton Mahoney Asset Management bought a new position in Glaukos during the 4th quarter worth about $125,000. SBI Securities Co. Ltd. purchased a new position in Glaukos during the 4th quarter valued at about $153,000. Finally, Smartleaf Asset Management LLC raised its holdings in shares of Glaukos by 275.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier's stock valued at $164,000 after purchasing an additional 807 shares in the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.

Glaukos Stock Performance

Shares of NYSE GKOS traded up $2.98 during midday trading on Wednesday, reaching $100.07. The company had a trading volume of 810,071 shares, compared to its average volume of 607,015. Glaukos Co. has a 1 year low of $89.94 and a 1 year high of $163.71. The business's 50-day simple moving average is $126.91 and its 200 day simple moving average is $135.14. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The stock has a market cap of $5.66 billion, a P/E ratio of -34.87 and a beta of 0.99.

Remove Ads

Glaukos (NYSE:GKOS - Get Free Report) last issued its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.02). The firm had revenue of $105.50 million during the quarter, compared to analysts' expectations of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. On average, analysts forecast that Glaukos Co. will post -1.08 earnings per share for the current fiscal year.

Insider Activity at Glaukos

In related news, CFO Alex R. Thurman sold 1,520 shares of the firm's stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total transaction of $162,396.80. Following the sale, the chief financial officer now owns 53,431 shares in the company, valued at approximately $5,708,568.04. This trade represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Tomas Navratil sold 3,416 shares of the company's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the transaction, the insider now owns 72,437 shares of the company's stock, valued at approximately $10,658,380.18. This trade represents a 4.50 % decrease in their position. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on GKOS shares. UBS Group assumed coverage on shares of Glaukos in a report on Friday, December 6th. They set a "buy" rating and a $182.00 price objective on the stock. Needham & Company LLC lifted their price target on Glaukos from $149.00 to $176.00 and gave the company a "buy" rating in a report on Friday, February 21st. Mizuho raised Glaukos from a "neutral" rating to an "outperform" rating and boosted their price target for the stock from $140.00 to $200.00 in a research report on Wednesday, February 19th. Stifel Nicolaus raised their price objective on Glaukos from $153.00 to $175.00 and gave the company a "buy" rating in a research report on Tuesday, December 31st. Finally, Piper Sandler reiterated an "overweight" rating and issued a $180.00 target price (up from $140.00) on shares of Glaukos in a report on Monday, January 27th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $163.25.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.